Viroblock SA Masks for #Coronavirus Press Release & Retail Information

Geneva, Switzerland, June 26, 2013 -- Viroblock SA, a Swiss start-up, today presented new data at ICPIC 2013 in Geneva, showing that their face-mask containing proprietary novel cholesterol depletion technology traps and kills over 99.9995% of H1N1 flu viruses (swine flu), 99.999% of H5N1 flu viruses (avian flu) and 99.997% human corona viruses on pass through air. Aimed at helping protect people from these respiratory pathogens, the mask is up to one hundred times more effective than a similar mask without Viroblock technology. The company will now start direct sales in Switzerland and is looking for distributors in other countries.
“Aerobiology tests for face-masks simulate real life situations, in which the user is exposed to viruses coming in. The mask helps prevent transmission from and to the person wearing the mask.” commented Dr Thierry Pelet, CSO at Viroblock. “The stringent testing demonstrates the efficacy and speed at which the cholesterol depletion technology works”.
Aerobiology tests, carried out in high security laboratories, create a mist of viruses on the outside of the mask, a pump is used to draw air and viruses through the mask, and finally testing for live virus occurs on the inside of the mask.
“We believe that our protective face-mask can help protect healthcare, agriculture and security workers effectively, with added advantages of comfort of wear and easy identification,” said Dr Jamie Paterson, CEO of Viroblock.
-snip-
For further information, please contact:
Danièle Castle
Genevensis Healthcare Communications
T: +4179 202 66 67
Mail: info@genevensis.com

Our retailers

Here are our retailers locations, please feel free to contact us:

VIROBLOCK SA 

Chemin des Aulx 18  

1228 Plan-les-Ouates

Switzerland
Phone: +41 22 884 83 46
Fax: +41 22 794 66 65
Email: info@viroblock.com
Website: http://www.viroblock.com

VALMY SAS

La demi-lieue - Rue Benjamin Franklin
42300 Mably
France
Phone: +33 477 23 11 21
Fax: +33 477 72 54 57
Email: info@valmy.eu
Website: http://www.valmy.eu

http://www.viroblock.com/content/30-viroblock-press-release